Efficacy and safety of PD‐1 monoclonal antibody combined with interferon‐alpha 1b and anlotinib hydrochloride as the second‐line therapy in patients with unresectable advanced melanoma: A retrospective study

Documenti analoghi

• Transcriptomics analysis of LINC02202/XBP1 axis in melanoma: Implications for drug targeting and PD‐1 monoclonal antibody efficacy
  di: Yuanyuan Shang, et al.
  Pubblicazione: (2024)
• A phase II study to evaluate the safety and efficacy of anlotinib combined with toripalimab for advanced biliary tract cancer
  di: Mingzhen Zhou, et al.
  Pubblicazione: (2024)
• Surufatinib plus anti‐PD‐1/PD‐L1 antibody as second‐line therapy for advanced biliary tract cancer: A single‐centre investigator‐initiated trial
  di: Xinni Chen, et al.
  Pubblicazione: (2026)
• Soluble PD‐L1 predicts tumor response and immune‐related adverse events in patients with advanced melanoma treated with anti–PD‐1 antibodies
  di: Kazumasa Oya, et al.
  Pubblicazione: (2024)
• Efficacy and safety of hepatic arterial infusion chemotherapy combined with donafenib in the treatment of unresectable hepatocellular carcinoma
  di: Tao Wan, et al.
  Pubblicazione: (2024)